These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 16520399)

  • 1. Impaired capacity for stimulated fibrinolysis in primary hypertension is restored by antihypertensive therapy.
    Ridderstråle W; Ulfhammer E; Jern S; Hrafnkelsdóttir T
    Hypertension; 2006 Apr; 47(4):686-91. PubMed ID: 16520399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of lisinopril, irbesartan, and amlodipine on the thrombogenic variables in the early and late stages of the treatment in hypertensive patients.
    Tiryaki O; Usalan C; Buyukhatipoglu H; Sayiner ZA; Kilisli H
    Clin Exp Hypertens; 2012; 34(2):145-52. PubMed ID: 21967026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impaired fibrinolytic capacity in hypertension is unaffected by acute blood pressure lowering.
    Ridderstråle W; Saluveer O; Carlström M; Jern S; Hrafnkelsdóttir TJ
    J Thromb Thrombolysis; 2011 Nov; 32(4):399-404. PubMed ID: 21614456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fibrinolysis and insulin sensitivity in imidapril and candesartan (FISIC study) recipients with hypertension.
    Fogari R; Zoppi A; Salvadeo SA; Mugellini A; Lazzari P; Santoro T; Derosa G
    Hypertens Res; 2011 Apr; 34(4):509-15. PubMed ID: 21179101
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impaired endothelial release of tissue-type plasminogen activator in patients with chronic kidney disease and hypertension.
    Hrafnkelsdóttir T; Ottosson P; Gudnason T; Samuelsson O; Jern S
    Hypertension; 2004 Sep; 44(3):300-4. PubMed ID: 15249548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiotensin-converting enzyme inhibition increases human vascular tissue-type plasminogen activator release through endogenous bradykinin.
    Pretorius M; Rosenbaum D; Vaughan DE; Brown NJ
    Circulation; 2003 Feb; 107(4):579-85. PubMed ID: 12566370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Additional antihypertensive effect of drugs in hypertensive subjects uncontrolled on diltiazem monotherapy: a randomized controlled trial using office and home blood pressure monitoring.
    Karotsis AK; Symeonidis A; Mastorantonakis SE; Stergiou GS;
    Clin Exp Hypertens; 2006 Oct; 28(7):655-62. PubMed ID: 17060064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bradykinin type 2 receptor BE1 genotype influences bradykinin-dependent vasodilation during angiotensin-converting enzyme inhibition.
    Van Guilder GP; Pretorius M; Luther JM; Byrd JB; Hill K; Gainer JV; Brown NJ
    Hypertension; 2008 Feb; 51(2):454-9. PubMed ID: 18180402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nitric oxide modulates tissue plasminogen activator release in normotensive subjects and hypertensive patients.
    Giannarelli C; De Negri F; Virdis A; Ghiadoni L; Cipriano A; Magagna A; Taddei S; Salvetti A
    Hypertension; 2007 Apr; 49(4):878-84. PubMed ID: 17339540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antihypertensive drugs and fibrinolytic function.
    Fogari R; Zoppi A
    Am J Hypertens; 2006 Dec; 19(12):1293-9. PubMed ID: 17161777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An in vivo model for the assessment of acute fibrinolytic capacity of the endothelium.
    Newby DE; Wright RA; Ludlam CA; Fox KA; Boon NA; Webb DJ
    Thromb Haemost; 1997 Oct; 78(4):1242-8. PubMed ID: 9364992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of angiotensin II receptor blockade and the DASH diet on markers of endogenous fibrinolysis.
    Erlinger TP; Conlin PR; Macko RF; Bohannon AD; Miller ER; Moore TJ; Svetkey LP; Appel LJ
    J Hum Hypertens; 2002 Jun; 16(6):391-7. PubMed ID: 12037693
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Marked impairment of protease-activated receptor type 1-mediated vasodilation and fibrinolysis in cigarette smokers: smoking, thrombin, and vascular responses in vivo.
    Lang NN; Gudmundsdóttir IJ; Boon NA; Ludlam CA; Fox KA; Newby DE
    J Am Coll Cardiol; 2008 Jul; 52(1):33-9. PubMed ID: 18582632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of candesartan and lisinopril on the fibrinolytic system in hypertensive patients.
    Hirschl MM; Bur A; Woisetschlaeger C; Derhaschnig U; Laggner AN
    J Clin Hypertens (Greenwich); 2007 Jun; 9(6):430-5. PubMed ID: 17541328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. B1 kinin receptor does not contribute to vascular tone or tissue plasminogen activator release in the peripheral circulation of patients with heart failure.
    Cruden NL; Tse GH; Fox KA; Ludlam CA; Megson I; Newby DE
    Arterioscler Thromb Vasc Biol; 2005 Apr; 25(4):772-7. PubMed ID: 15681300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of nisoldipine and lisinopril on microvascular dysfunction in hypertensive Type I diabetes patients with nephropathy.
    Sørensen VB; Rossing P; Tarnow L; Parving H; Nørgaard T; Kastrup J
    Clin Sci (Lond); 1998 Dec; 95(6):709-17. PubMed ID: 9831696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vascular and fibrinolytic effects of intra-arterial tumour necrosis factor-alpha in patients with coronary heart disease.
    Robinson SD; Dawson P; Ludlam CA; Boon NA; Newby DE
    Clin Sci (Lond); 2006 Mar; 110(3):353-60. PubMed ID: 16309383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impaired capacity for acute endogenous fibrinolysis in smokers is restored by ascorbic acid.
    Kaehler J; Koeke K; Karstens M; Schneppenheim R; Meinertz T; Heitzer T
    Free Radic Biol Med; 2008 Feb; 44(3):315-21. PubMed ID: 18215739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Rahman M; Pressel S; Davis BR; Nwachuku C; Wright JT; Whelton PK; Barzilay J; Batuman V; Eckfeldt JH; Farber M; Henriquez M; Kopyt N; Louis GT; Saklayen M; Stanford C; Walworth C; Ward H; Wiegmann T
    Arch Intern Med; 2005 Apr; 165(8):936-46. PubMed ID: 15851647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Release of tissue-type plasminogen activator in response to muscarinic receptor stimulation in human forearm.
    Jern S; Selin L; Bergbrant A; Jern C
    Thromb Haemost; 1994 Oct; 72(4):588-94. PubMed ID: 7878638
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.